RIGEL PHARMACEUTICALS INC RIGL

Rank #1708 · Nasdaq · $0.9B market cap

Audited by Ernst & Young LLP, no going-concern flag in the latest filing.

Score

43.9

P/E

-37.8

P/B

-69.72

ROE

184.3%

Op. Margin

-17.5%

Debt Ratio

-1180%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Poor

P/E -37.8x, P/B -69.72x. Ranks in the top 86% of the universe.

Profitability ★★★☆☆

Average

ROE 184.3%. Ranks in the top 41% of the universe.

Safety ★★★★★

Excellent

Debt ratio -1180%. Ranks in the top 2% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆

Weak

Revenue decline of 2.8% year over year. Ranks in the top 72% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2011	–	$-0.1B	–	$0.1B	–	79
2012	–	$0.0B	–	$0.1B	–	134
2013	–	$-0.1B	–	$0.2B	–	87
2014	–	$-0.1B	–	$0.2B	–	-4
2015	–	$-0.1B	–	$0.3B	–	-47
2016	–	$-0.1B	–	$0.2B	–	-37
2017	–	$-0.1B	$-0.1B	$0.1B	–	-39
2018	$0.0B	$-0.1B	$-0.1B	$0.1B	-342.2	30
2019	$0.0B	$-0.1B	$-0.1B	$0.1B	-1775.6	153
2020	$0.0B	$-0.1B	$-0.1B	$0.1B	-163.3	47
2021	$0.1B	$-0.1B	$-0.1B	$0.1B	-116.5	0
2022	$0.1B	$-0.0B	$-0.0B	$0.1B	-26.7	254
2023	$0.1B	$-0.0B	$-0.0B	$0.0B	-8.4	435
2024	$0.1B	$-0.1B	$-0.1B	$0.0B	-46.2	480
2025	$0.1B	$-0.0B	$-0.0B	$-0.0B	-17.5	-1180